RT Journal Article SR Electronic T1 Accuracy and cost-effectiveness of dynamic contrast-enhanced CT in the characterisation of solitary pulmonary nodules—the SPUtNIk study JF BMJ Open Respiratory Research JO BMJ Open Resp Res FD British Thoracic Society SP e000156 DO 10.1136/bmjresp-2016-000156 VO 3 IS 1 A1 N R Qureshi A1 R C Rintoul A1 K A Miles A1 S George A1 S Harris A1 J Madden A1 K Cozens A1 L A Little A1 K Eichhorst A1 J Jones A1 P Moate A1 C McClement A1 L Pike A1 D Sinclair A1 W L Wong A1 J Shekhdar A1 R Eaton A1 A Shah A1 L Brindle A1 C Peebles A1 A Banerjee A1 S Dizdarevic A1 S Han A1 F W Poon A1 A M Groves A1 L Kurban A1 A J Frew A1 M E Callister A1 P Crosbie A1 F V Gleeson A1 K Karunasaagarar A1 O Kankam A1 F J Gilbert YR 2016 UL http://bmjopenrespres.bmj.com/content/3/1/e000156.abstract AB Introduction Solitary pulmonary nodules (SPNs) are common on CT. The most cost-effective investigation algorithm is still to be determined. Dynamic contrast-enhanced CT (DCE-CT) is an established diagnostic test not widely available in the UK currently.Methods and analysis The SPUtNIk study will assess the diagnostic accuracy, clinical utility and cost-effectiveness of DCE-CT, alongside the current CT and 18-flurodeoxyglucose-positron emission tomography) (18FDG-PET)-CT nodule characterisation strategies in the National Health Service (NHS). Image acquisition and data analysis for 18FDG-PET-CT and DCE-CT will follow a standardised protocol with central review of 10% to ensure quality assurance. Decision analytic modelling will assess the likely costs and health outcomes resulting from incorporation of DCE-CT into management strategies for patients with SPNs.Ethics and dissemination Approval has been granted by the South West Research Ethics Committee. Ethics reference number 12/SW/0206. The results of the trial will be presented at national and international meetings and published in an Health Technology Assessment (HTA) Monograph and in peer-reviewed journals.Trial registration number ISRCTN30784948; Pre-results.